PMV

PMV Pharmaceuticals is a precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies. The company utilizes a proprietary platform to target and structurally correct specific mutant p53 proteins, aiming to restore their natural tumor-suppressing function. This approach allows for the development of highly selective treatments addressing a significant underlying cause of many cancers.

The company was founded in 2013 by David Mack, Ph.D., Arnold Levine, Ph.D., and Thomas Shenk, Ph.D. Their founding insight stemmed from Dr. Levine’s groundbreaking discovery of the p53 protein in 1979, which established the field of p53 biology. PMV Pharmaceuticals leverages this foundational research and decades of collective experience, including Dr. Mack's background in biotech venture capital and genomics, to advance their therapeutic strategy.

PMV Pharmaceuticals aims to provide unique therapies for patients whose tumors harbor specific p53 gene mutations. The company's long-term vision is to fundamentally disrupt the course of cancer by precisely targeting these mutations, ultimately offering new treatment avenues for a broad range of cancers irrespective of their origin. They continue to build their precision oncology platform to achieve this goal.